Overview

Hemato Oncology Testing Market Introduction

Hemato Oncology Testing Market is estimated to value over USD 7.2 billion by 2027 end and register a CAGR of over 14.6% during the forecast period 2020 to 2027.

The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment.
Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period.

Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits.

Global Hemato Testing Oncology Market Regional Insight

The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products.

Major Key Players in Hemato Oncology Testing Market :
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Illumine Inc.
• Molecular MD
• Invivoscribe Inc.
• Qiagen N.V.
• Bio-Rad Laboratories, Inc.
• Archerdx, Inc.
• Arup Laboratories Inc.
• Asuragen, Inc.
• Adaptive Biotechnologies.
• Cepheid
• Entrogen, Inc.

Hemato Oncology Testing market

Hemato Testing Oncology Market Segmentation:

By Region
• North America
• Europe
• Asia Pacific
• Rest of the World

By Product & Service Type
• Services
• Assay Kits

By Cancer Type
• Leukemia
o Acute Myeloid Leukemia (AML)
o Acute Lymphocytic Leukemia (ALL)
o Chronic Lymphocytic Leukemia
o Chronic Myeloid Leukemia
• Lymphoma
o Non-Hodgkin Lymphoma
o Hodgkin Lymphoma
• Myeloproliferative Neoplasms
o Polycythemia vera (PV)
o Essential thrombocythemia (ET)
o Myelofibrosis (MF)
• Other Cancers

By Technology
• PCR
o Real-time qPCR
o Digital PCR
• NGS
• IHC
• Cytogenetics
• Others

By End User
• Clinical laboratories
• Hospitals
• Academic & Research Institutes
• Other End Users (CROs, Pharmaceutical & Biotechnology Companies)

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Hemato Oncology Testing Market By Product & Service Type, By Cancer Type, By Technology, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization services offered are free of charge with purchase of any license of the report.
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com